Rx for Biotech: Recent Episodes
Podcast Host Chris Leidli
The Rx for Biotech podcast explores the changing health care delivery landscape. The Rx for Biotech podcast features audio interviews with the physicians, scientists, investors and biotechnology leaders who share their insights, experience and knowledge so that companies can successfully launch therapeutics to ensure patient access to innovative treatments.
Can artificial intelligence help cancer patients understand their diagnosis, find more personalized treatment options, and become better advocates for their own care?In this episode of Rx for Biotech, I met with Steve Brown, Founder and CEO of CureWise, an AI-powered patient advocacy platform designed to help people with cancer better understand their disease, prepare questions for their doctors, and explore precision oncology treatment options.For Steve, this mission is deeply personal.After months of unexplained health problems, Steve was ultimately diagnosed with amyloidosis, a rare plasma cell disorder closely related to multiple myeloma. He began using AI agents to analyze his medical records, laboratory results, biopsies, and emerging medical research. Rather than replacing his physicians, AI helped Steve identify patterns, understand the significance of his individual disease biology, and ask more informed questions of specialists.That experience ultimately helped inspire CureWise.In our conversation, Steve explains why he believes the next generation of AI in healthcare should go far beyond simply asking ChatGPT a medical question. CureWise brings together a patient's longitudinal medical information and uses multiple AI models to examine the case from different perspectives - helping patients better understand their cancer and participate more effectively in shared decision-making. The broader vision is not to replace oncologists, but to give patients a more powerful educational and advocacy tool.We also dig into one of the most important ideas in precision cancer care: cancer isn't defined only by where a tumor starts. Increasingly, genomic and molecular testing can reveal mutations and biomarkers that may influence targeted therapies, clinical trials, and other treatment strategies.In this episode:•Steve's personal journey from unexplained symptoms to a rare cancer diagnosis•How he used AI to analyze his medical records•Why AI should support—not replace—oncologists•How CureWise uses multiple AI models to evaluate complex medical information•Why genomic sequencing and biomarker testing matter in precision oncology•Standard-of-care cancer treatment vs. personalized treatment strategies•How patients can prepare more effectively for oncology appointments•AI and clinical trial matching•Why rare molecular subtypes challenge traditional clinical trial models•How AI could democratize access to expertise associated with major cancer centers•The importance of patient advocacy and shared decision-making•Steve's vision for using patient data and AI to accelerate future cancer researchSteve's philosophy is particularly relevant for patients and caregivers: AI doesn't have to make the medical decision to be valuable. It can help patients understand the landscape, identify important questions, and participate more effectively in decisions with their oncology team.CureWise was built around that idea- that helping patients understand their specific cancer, identify questions to discuss with their oncology team, and explore clinical trials and emerging therapies that may be relevant to their care.If you or someone you love is navigating a cancer diagnosis, this conversation offers a provocative look at how artificial intelligence, genomic testing, precision medicine, and better patient education could change the cancer journey.Subscribe to Rx for Biotech for conversations with the scientists, physicians, entrepreneurs, and patients shaping the future of personalized medicine and advanced therapies.This episode is for educational purposes and does not provide medical advice. AI tools should not replace evaluation or treatment decisions by qualified healthcare professionals.#AIHealthcare #Cancer #CancerTreatment #PrecisionOncology #PrecisionMedicine #CancerResearch #GenomicTesting #PatientAdvocacy #ArtificialIntelligence #CancerCare #Biomarkers #ClinicalTrials #CureWise #RxForBiotech
Can stem cell therapy help repair damaged spinal discs instead of simply masking pain?Millions of people suffer from chronic low back pain and degenerative disc disease, yet today's standard treatments often focus on symptom management through pain medications, steroid injections, or invasive surgery. But what if regenerative medicine could change that?In this episode of Rx for Biotech, host Chris Leidli sits down with Lance Alstodt, CEO of BioRestorative Therapies, to explore how the company is developing next-generation regenerative medicine platforms designed to restore function—not just relieve symptoms.Lance discusses BioRestorative's lead clinical program, BRTX-100, an investigational autologous stem cell therapy currently in Phase 2 clinical development for chronic lumbar disc disease. The conversation explores how stem cells are expanded using the company's proprietary hypoxic manufacturing process before being injected directly into damaged spinal discs in an effort to promote tissue repair.The discussion also looks beyond spine health to BioRestorative's ThermoStem® platform, which is investigating the potential of brown adipose (brown fat) stem cells to improve metabolic health and complement GLP-1 weight-loss therapies. Finally, Lance explains how the company's expertise in stem cells and exosome biology is also being applied to next-generation skincare and regenerative aesthetics.In this episode you'll learn:•Why chronic low back pain remains one of healthcare's largest unmet needs•How regenerative medicine differs from traditional pain management•The science behind BRTX-100 and autologous stem cell therapy•Why BioRestorative uses proprietary hypoxic cell expansion•Current Phase 2 clinical trial progress and safety observations•The future of regenerative medicine for orthopedic diseases•How brown fat stem cells could complement GLP-1 therapies•What exosomes are—and why not all exosomes are created equal•The difference between FDA-regulated cell therapies and many commercial regenerative medicine clinics•BioRestorative's long-term vision for restoring function instead of simply managing symptomsWhether you're a patient living with chronic back pain, a healthcare professional, an investor, or simply interested in the future of regenerative medicine, this episode provides an inside look at one of the most exciting areas of biotechnology.
In this episode, you'll learn:• What radioligand therapy (RLT) is• How theranostics works• The difference between traditional radiation and targeted radiopharmaceutical therapy• How imaging helps personalize treatment• Why prostate cancer and neuroendocrine tumor patients are benefiting today• What patients can expect during treatment• Common side effects and safety considerationsIf you or someone you love has been diagnosed with cancer, this conversation is a good educational primer to one of the most promising advances in oncology.Subscribe for more patient-focused conversations on cancer treatment, precision medicine, immunotherapy, cell therapy, and healthcare innovation.#CancerTreatment #RadioligandTherapy #Theranostics #ProstateCancer #NeuroendocrineTumors #PrecisionMedicine
What does it really take to successfully launch a radiopharmaceutical?In Part 1 of this special roundtable “Rx for Biotech” podcast series, Chris Leidli met with Dr. Babak Saboury and Dr. Eliot Siegel, founders of United Theranostics and nationally recognized leaders in nuclear oncology, to discuss one of the biggest challenges facing the radiopharmaceutical industry today: building the infrastructure to expand patient access to these innovative medicines.While radioligand therapies (RLTs) and theranostics are generating unprecedented excitement in oncology, many pharmaceutical companies underestimate the complexity of delivering these therapies to patients.In this episode, we discuss:• Why only a small percentage of eligible patients currently receive radioligand therapy• Site readiness, staffing, and infrastructure challenges• Why traditional pharmaceutical launch models often fail in radiopharmaceuticals• Building sustainable access for patients• What pharmaceutical companies should understand before launching an RLTThis conversation offers a front-line perspective on what it will take to scale the future of radiopharmaceutical medicine.🎧 Subscribe for more conversations on radiopharmaceuticals, precision medicine, oncology, targeted therapies, and advanced therapies.#Radiopharmaceuticals #RadioligandTherapy #Theranostics #PrecisionMedicine #Oncology #NuclearMedicine #Pharma #Biotech #HealthcareInnovation #RxForBiotech
What if AI could help women better understand their bodies and take control of their health before problems become crises?In this episode of #RxforBiotech, host Chris Leidli sits down with Kirsten Karchmer, Founder and CEO of Conceivable, to discuss the future of women's health, fertility, hormone health, and personalized medicine.After helping more than 10,000 women improve their fertility and reproductive health over the past 25 years, Kirsten is now building an AI-powered operating system designed to help women understand the root causes of health challenges rather than simply treating symptoms.From fertility and PCOS to fatigue, hormone imbalances, perimenopause, and menopause, Conceivable combines artificial intelligence, wearable data, lifestyle insights, and personalized coaching to help women make informed decisions about their health.In this episode, we discuss:• Why so many women feel dismissed by the healthcare system• The future of AI in women's health• Fertility treatment and reproductive health• Personalized medicine and hormone optimization• The role of wearables, biomarkers, and health data• Menopause, perimenopause, and healthy aging• How AI can help women become advocates for their own health• Why understanding the root cause matters more than treating symptomsWhether you're trying to conceive, navigating hormone changes, managing a chronic condition, or simply interested in the future of healthcare, this conversation offers an inspiring look at how technology can empower women throughout every stage of life.🎧 Subscribe for more conversations on healthcare innovation, precision medicine, AI, women's health, and advanced therapies.
COO of Immunic Therapeutics, to discuss the evolving future of treatment for Multiple Sclerosis (MS), one of the most complex autoimmune and neurodegenerative diseases affecting millions worldwide.Jason shares his deep experience leading major MS franchises at Biogen and Novartis, explains how MS attacks the brain and spinal cord, and breaks down why many current therapies focus primarily on inflammation but may not fully address the neurodegeneration driving long-term disability.The conversation also explores Immunic’s lead investigational therapy, vidofludimus calcium, an oral once-daily treatment being studied in Phase 3 clinical trials for relapsing multiple sclerosis. The company believes the therapy may offer a unique dual approach by targeting both neuroinflammation and neurodegeneration.Topics discussed include:• What causes multiple sclerosis• Early symptoms and diagnosis of MS• How MRI imaging transformed MS care• Why MS remains difficult to treat• The difference between inflammation and neurodegeneration• Oral therapies vs infusions and injectables• Progressive multiple sclerosis and unmet patient needs• The future of neuroscience, immunotherapy, and personalized medicineFor patients, caregivers, healthcare providers, and anyone interested in the future of neurology and autoimmune disease treatment, this episode offers an accessible and hopeful look at where MS care may be headed next.
What if your own immune cells could be engineered to fight and even cure cancer?In this episode of Rx for Biotech, host Chris Leidli sits down with Navneet Majhail, MD, a leading expert in blood cancers, bone marrow transplants, and CAR-T cell therapy, to break down one of the most powerful innovations in modern medicine: CAR-T therapy.CAR-T therapy is a form of immunotherapy that uses a patient’s own T cells - engineered in a lab - to recognize and destroy cancer. It has already transformed outcomes for patients with leukemia, lymphoma, and multiple myeloma, offering hope where few options previously existed.But despite its promise, many eligible patients still don’t receive CAR-T therapy due to barriers like access, geography, insurance, and care coordination.In this conversation, Dr. Majhail explains:• What CAR-T cell therapy is and how it works• Why access to treatment remains a major challenge• The role of bone marrow transplant and cellular therapy networks• How care is shifting closer to home through community-based treatment models• The importance of caregivers and support systems during treatment• What the future holds for CAR-T in solid tumors, autoimmune diseases, and beyondThis episode is a must-watch for patients, caregivers, and anyone interested in the future of personalized cancer treatment, immunotherapy, and advanced therapies
Why is brain cancer so hard to detect and treat - and what if we could change that?In this episode of Rx for Biotech, host Chris Leidli sits down with Marc Hedrick, CEO of Plus Therapeutics, and Russell Bradley, General Manager of CNSide Diagnostics, to explore a new, integrated approach to treating some of the most challenging cancers in medicine: central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases.Brain and CNS cancers are among the most difficult to treat because of the blood-brain barrier, which prevents most drugs from reaching tumors. In fact, only a small percentage of therapies can effectively cross into the brain—limiting treatment options and outcomes.Plus Therapeutics is tackling this problem with a novel approach using targeted radiation therapy delivered directly to tumors, bypassing the blood-brain barrier. Their lead program uses a radioactive isotope (rhenium-186) delivered via nanoliposomes, allowing high doses of radiation to reach the tumor while minimizing damage to the rest of the body.At the same time, CNSide Diagnostics is helping physicians detect cancer earlier and monitor treatment response using an advanced cerebrospinal fluid (CSF) diagnostic test. This highly sensitive test can identify even small numbers of tumor cells—helping doctors make faster, more informed treatment decisions.Together, this combination of diagnostics + therapeutics + data represents a new model for precision oncology and personalized cancer care.In this episode, we discuss:• Why brain cancer is so difficult to treat• The role of the blood-brain barrier in limiting therapies• How targeted radiation therapy can improve outcomes• The importance of early detection and diagnostics• How monitoring tumor cells can guide treatment decisions• The future of integrated cancer care (theranostics)This conversation offers a powerful look at how innovation in both treatment and diagnostics could help improve survival and quality of life for patients with some of the most aggressive cancers.
What if you could get a Transplant and Reset your Immune System in less than 48 Hours?In this episode of Rx for Biotech, host Chris Leidli sits down with Kevin Caldwell, CEO of Ossium Health, to explore how bone marrow transplants, cell therapy, and bioengineered immune systems are transforming the future of medicine.Ossium Health is building a first-of-its-kind bone marrow banking platform, using donor-derived cells to make life-saving treatments available on demand. Traditionally, patients can wait months to find a donor match - time many simply don’t have. Ossium is changing that by enabling transplants in as little as 48 hours, dramatically improving access to care.In this conversation, Kevin explains how bone marrow transplants work, why they are one of the most powerful tools in modern medicine, and how replacing a patient’s blood and immune system can treat diseases like blood cancers and immune disorders.We also dive into:• Why most eligible patients never receive a bone marrow transplant• How off-the-shelf cell therapy could scale life-saving treatments• The role of the immune system in preventing disease and cancer• How donor-derived cells could unlock the future of regenerative medicine and longevity• Why improving immune health may be one of the most powerful ways to extend human lifeAs cell therapy and regenerative medicine continue to evolve, Ossium’s approach could help shift healthcare from reactive treatment to proactive, personalized immune system care.📌 Learn more about how to navigate the healthcare system and find the right specialists:https://therapy4me.ai
What if chemotherapy could target tumors without harming the rest of the body?In this episode of Rx for Biotech, host Chris Leidli sits down with Christina Coughlin, MD, PhD, CEO of Avacta Therapeutics, to explore a new approach to cancer treatment using targeted chemotherapy and precision oncology.Avacta is developing a novel platform designed to activate powerful cancer drugs only inside the tumor, potentially reducing side effects like damage to the heart, bone marrow, and other healthy tissues. This approach, known as tumor-targeted drug delivery, could redefine how chemotherapy is used across cancers such as triple-negative breast cancer, soft tissue sarcoma, and salivary gland cancer.Christina shares her journey from early work in CAR-T cell therapy and immuno-oncology to leading Avacta’s innovative pre|CISION peptide drug conjugate platform, including its lead asset AVA6000 (faridoxorubicin) now in clinical trials.In this conversation, we discuss:• How targeted chemotherapy works and why it may be safer than traditional chemo• The role of the immune system and immunotherapy in cancer treatment• Why improving drug delivery is one of the biggest challenges in oncology• Key clinical insights from early trials of AVA6000• What the future of precision medicine and personalized cancer care could look likeAs cancer treatment evolves, innovations like Avacta’s platform could help patients receive more effective, less toxic therapies tailored to their biology📌 Learn more about navigating advanced therapies and personalized care at: [https://www.therapy4me.ai]#CancerTreatment #PrecisionMedicine #Chemotherapy #Immunotherapy #Oncology #Biotech #TargetedTherapy #Avacta #RxForBiotech
What if a simple blood test could reveal how your body responds to disease - or even help doctors choose the right treatment for you?In this episode of Rx for Biotech, host Chris Leidli speaks with Mo Jain, MD, PhD, co-founder of Sapient, about how scientists are using advanced biology and artificial intelligence to uncover new biomarkers - the biological signals that can help doctors understand what’s happening inside the body.Biomarkers are becoming one of the most important tools in precision medicine, helping physicians move beyond one-size-fits-all treatments toward care that is tailored to each patient’s unique biology.Mo explains how Sapient is analyzing thousands of human samples using advanced technologies to better understand metabolism, disease progression, and how patients respond to therapies. These insights could help improve early diagnosis, guide treatment decisions, and empower patients with more personalized health information.In this conversation, you’ll learn:• What biomarkers are and why they matter for patients• How AI and advanced biology are helping scientists discover new health insights• Why understanding your body’s metabolism can change how diseases are treated• How biomarker data could help patients and doctors make better care decisionsAs medicine becomes more personalized, having the right biological information may become one of the most powerful tools patients have to advocate for their own care.For additional patient education and support, visit:https://therapy4me.ai
, host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).We discuss: How PSMA-targeted radioligand therapy delivers radiation directly to cancer cells The role of innovation in advanced and metastatic prostate cancer Expanding patient access to cutting-edge therapies Why patient advocacy and education matter in modern oncologyAs prostate cancer remains one of the most common cancers in men, new treatment approaches like radioligand therapy are redefining what’s possible for patients living with advanced prostate cancer.
What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer’s? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body.This conversation offers a hopeful look at how science is working to improve quality of life for patients and families facing neurodegenerative disease.Arun also shares insights from his 20+ years in biotech leadership, including what it takes to advance novel immunology science in high-unmet-need indications and build a product pipeline across neurodegenerative, autoimmune, and inflammatory diseases.
A cancer diagnosis can feel overwhelming - but patients are not powerless.In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.
This episode is about hope, and about a different way of thinking about cancer treatment.My guest is Dr. Øystein Rekdal, CEO and co-founder of Lytix Biopharma. Øystein is a scientist and leader who has spent decades studying how the immune system works - and how it can be helped to recognize and fight cancer more effectively.Rather than focusing only on destroying tumors, Lytix is working on therapies designed to wake up the immune system and help it remember cancer as a threat. It’s an approach that aims not just to treat disease, but to support the body’s own ability to respond.This is a conversation for anyone who wants to better understand where cancer care is headed, and why there’s real reason for optimism.
InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.
In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.
In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.
In this episode of Rx for Biotech, host Chris Leidli sits down with Dr. Frank Bedu-Addo, CEO of PDS Biotechnology, to discuss how the company is reimagining immunotherapy with its proprietary Versamune® T-cell activating platform.
Early cancer detection doesn't have to mean invasive tests. In this podcast episode, we sit down with Jeff Bousfield, CEO of Nonacus Cancer Diagnostics, to explore how his UK-based company is revolutionizing precision cancer diagnostics with a powerful suite of non-invasive tools. Jeff shares the human story behind the science and why he believes the future of cancer care starts with precision diagnostics tools that are faster, less invasive, and more accessible to patients.
Metastatic pancreatic cancer remains one of the deadliest cancers, but a new approach is taking shape - and it's showing promise in early clinical studies. In this episode, Dan Schmitt, President and CEO of Actuate Therapeutics, shares how elraglusib, an investigational targeted therapy, may provide a new option for patients with metastatic pancreatic cancer. We explore the urgent unmet need and why Dan thinks this could be a turning point for one of oncology's toughest challenges.
In this podcast episode, Dr. Kilian Kelly, CEO of Cynata Therapeutics, discusses the future of regenerative medicine! Discover how mesenchymal stem cells (MSCs)—powerful cells that repair and regenerate tissues—are revolutionizing treatments for a range of diseases. Dr. Kelly shares insights on Cynata’s groundbreaking Cymerus™ platform and the exciting potential of MSC therapies.
Our guest in this podcast episode is lymphoma survivor and CAR-T cell therapy patient advocate, Brad Watts. In this episode, Brad shares his personal story battling lymphoma at the young age of 29 along with his experience receiving an innovative cell therapy. This field is transforming lives and Brad is living proof of this potential.
AI is transforming job search, recruiting and hiring practices. Our guest in this podcast episode is Steve Swan, Practice Leader at The Swan Group. Steve is an Executive Recruiter specializing in technology for the Pharmaceutical and Biotech Industry. In this episode Steve shares his insights on how AI is transforming the hiring process.
Gene therapy offers significant hope for treating sickle cell disease (SCD), a genetic disorder caused by a single mutation in the hemoglobin gene. Recent advancements have led to promising developments and FDA approvals, but challenges remain. In this podcast episode, gene therapy survivor, Jimi Olaghere, shares his journey and offers hope to others with his inspirational message and through his advocacy for patients in the sickle cell community.
In this podcast episode, hear from Diakonos Oncology President and Chief Operating Officer Jay Hartenbach, who provides an update on the company's innovative dendritic cell vaccine therapy designed to tackle some of the most challenging cancers, including glioblastoma and pancreatic cancer
Dr. Thomas Chen is a world-renowned neurosurgeon, Director of Surgical Neuro-Oncology at the University of Southern California, and the founder and CEO of NeOnc Technologies. In this podcast episode we discuss the company’s unique approach to treating glioblastoma and other aggressive brain cancers.
Our guest in this podcast episode is Sreekanth Gopi, a leader in generative AI and machine learning. Sreekanth has applied AI to fields as diverse as physiological monitoring, meditation, and even generating multi-track Indian classical music. He’s published award-winning research on EEG spectral analysis and adaptive quiz generation using large language models, participated in over 12 AI hackathons—winning two—and is now a Prompt Engineer at Morgan Stanley, where he fine-tunes cutting-edge LLM interactions for real-world applications.In this episode we explore how AI is redefining stress management and revolutionizing real-time physiological data applications. Tune in to learn about the world of generative artificial intelligence— and looking at its transformative potential in mental health and stress management.
Arvinas is a biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. In this podcast episode, Dr. Randy Teel discusses the company's PROTAC protein degrader technology platform and its pipeline of clinical-stage assets, with a focus on vepdegestrant, the company's lead asset that is being co-developed together with partner Pfizer, for the treatment of women with early and locally advanced or metastatic ER+/HER2- breast cancer.
HLTH brings together all the ecosystem stakeholders each year to discuss the innovations that will help solve some of healthcare's biggest challenges. In this podcast episode, Noe Gutierrez, the Head of Commercial Operations at Genoplex, Inc., shares many of the key themes and insights from the biggest health tech conference of 2024.
Next Generation Gene Therapies is developing novel gene therapies for the treatment of many rare diseases. In this podcast episode, the company's Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company's dual-functional vector tech platform is being used to target many diseases.
Immunotherapies continue to redefine treatment for many types of cancer and one of the first immunotherapies approved and used clinically as a therapeutic is Interleukin-2, or IL-2. Aulos Bioscience is an immuno-oncology company that has developed AU-007, a potential best-in-class IL-2, that improves on many of the other IL-2 products in development. In this episode, we discuss the promise of AU-007 with President and CEO, Aron Knickerbocker. Link to Interleukin-2 review article can be found here: https://www.nature.com/articles/s41587-022-01390-3
In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease. Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases.Link to NMOSD video mentioned in episode: https://www.youtube.com/playlist?list=PLJQx_6LtucSB9GGeiWTycLm7wjK_LX0ZI
In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.
In this podcast episode, Dr. James Zou, Associate Professor of Biomedical Data Science and Faculty DIrector of the AI for Health department at Stanford University, shares current use cases for AI in healthcare and oncology and discusses how we can overcome challenges with LLMs to unlock the full potential of AI.
In this episode, Genoplex Founder and CEO, Chris Leidli, and CTO, Shoukri Kattan, take a dive deep into their shared passion for health, wellness, and longevity, and explore how technology is revolutionizing patient access to advanced therapies. Chris and Shoukri discuss the groundbreaking work happening at Genoplex, including how the company's Advanced Therapy Connect digital platform is transforming the way patients connect with life-changing treatments.
Our guest for this podcast episode is Robb Richards, Corporate Director of Cell Therapy and Transplant at University of Pennsylvania, Penn Medicine. In this episode, we discuss how Penn Medicine is working to improve patient access to cellular therapies and how technology has evolved to streamline operational and clinical workflows to enhance patient experience.
Our guest for this episode is Balaji Gopalan, CEO and Co-Founder of MedStack where we discuss how MedStack's tech stack is enabling digital health start-ups to be healthcare data compliant. MedStack streamlines compliance with out-of-the-box HIPAA controls and ready-to-use privacy policies, enabling the faster and more cost-effective development of digital health applications. With built-in security controls and third-party validation, MedStack is setting new standards in healthcare technology.
Our guest for this podcast episode is Mike Kelly, President & CEO of NervGen Pharma. NervGen is a clinical-stage biotech company at the forefront of developing treatments that empower the nervous system to repair itself following damage from injury or disease.
In this podcast episode, your host, Chris Leidli, MS, MBA, goes beyond the ASCO 2024 headlines and puts a spotlight on the new clinical data for advanced therapies you don't want to miss.
In this episode, we preview the top American Society of Gene and Cell Therapy (ASGCT) 2024 annual meeting abstracts with guests Dr. Emily Walsh Martin from Tremont Therapeutics Consulting and Lynnea Olivarez, Incoming Chair of the ASGCT Communications Committee.
Over the years, electronic health records (EHRs) have revolutionized medical practice, digitizing patient data and streamlining care. But the current systems are not well suited to support collection of real-world data or the tracking of longitudinal outcomes across patient populations. This is particularly true for hematopoietic stem cell transplant and cellular therapies. Our special guest, Dr. Wayne Liang is a leader in the stem cell transplant and cell therapy informatics field. Wayne is Director of Informatics Education and Outreach at Children's Healthcare of Atlanta, he is also a pediatric hematologist/oncologist at Aflac Cancer & Blood Disorders Center, and Assistant Professor of Pediatrics at Emory University.
Our guest for this podcast episode is Simon Arkell, CEO of Ryght. Ryght is developing the next generation of safe and secure generative AI to empower Life Science companies to ingest real-time data and make actionable knowledge directly available to discovery, clinical, and commercial teams.
Our guest for this podcast episode is Doron Behar, MD, PhD, co-founder and CEO of Igentify, a digital health, artificial intelligence and genetic counseling company. In this episode, Dr. Behar shares how his company has developed a medical-grade tech platform that optimizes genomic workflows and produces AI-generated personalized genetic counseling for patients.
This episode features a preview of the American Society of Gene and Cell Therapy Annual Meeting scientific symposium on the impact of Generative AI on cell and gene therapy (CGT); best practices and real-world applications for communicators. Dr. Rory Bricker-Anthony shares insight into what attendees can expect to learn from the May 2024 session, including current tools and applications for CGT communicators.
Our guest in this podcast episode is Chris Dokomajilar, Founder and CEO of DealForma. DealForma’s comprehensive life science database includes meticulously researched licensing deal financial comps, up-to-date profiles, and historic company and pipeline data. In this special spotlight episode, we take a deeper dive into the investment landscape for advanced therapies and also AI investment and partnership activity in the biopharma space.
We often don’t get the chance to hear from survivors and patient advocates whose lives have been impacted by advanced medicines; so that makes this podcast episode special as we talk to Chris White, a cancer survivor who faced the unimaginable when diagnosed with Mucosal Melanoma in 2018—a rare and aggressive cancer which makes Chris's journey even more exceptional.Today, Chris is not just a survivor; he's a beacon of inspiration. He has redirected his energy towards advocacy, prevention, and raising awareness of the complexities associated with Mucosal Melanoma. Tune in to listen to Chris's extraordinary odyssey, exploring the challenges he faced throughout his treatment journey and proving that with resilience, determination, and hope, anything is possible.
Our guest for this podcast episode is Mark Carbone, the CEO of PN Medical. PN Medical is a leader in respiratory care and research. The company created “The Breather”, the world’s first combined respiratory muscle training device to strengthen respiratory muscles to optimize blood flow, lung function and strengthen the cardiopulmonary system.
In part 2 of this special round table podcast series, we discuss the future trends and advances in cell therapy manufacturing and the impact of AI on the evolving cell therapy analytics space.
In part 1 of this special round table podcast series, we discuss the current trends and advances in cell therapy manufacturing and the impact of evolving manufacturing processes on the analytics space.
Our guest for this podcast episode is Laura Hobbs, Director of Healthcare Policy at the American Action Forum. In this episode, we discuss the Inflation Reduction Act impact on Pharma and Patient Access, along with 340b drug pricing and new PBM utilization controls. Learn more about the American Action Forum, and subscribe to their weekly newsletter here: https://www.americanactionforum.org/
In this special episode, listen to Emily Walsh Martin, PhD, Principal at Tremont Therapeutics Consulting, as she shares some of the key highlights from the American Society of Gene and Cell Therapy’s Policy Summit that was held in Washington, DC, on September 18th and 19th, 2023.Check out the full program and register to view the on-demand content online at asgct.org/advocacy/policy-summit/agenda
The Inflation Reduction Act was signed into law in August 2022. In this podcast episode, we look into what lies ahead as the policy implementation begins. Our guest in this episode is Dr. Robert Popovian, a clinical pharmacist and health economist with deep expertise in health policy, drug pricing and affordability, access, and patient advocacy.
Our guests for this podcast episode are the co-founders of Ratio Therapeutics, CEO Jack Hoppin, PhD, and Chief Scientific Officer, John Babich, PhD. Ratio Therapeutics's mission is to develop best-in-class radiopharmaceuticals for the treatment of cancers.
Listen to Francesca Cook, VP of Market Access at Regenexbio, as she provides an overview of the program and what to expect at the American Society of Gene and Cell Therapy’s upcoming Policy Summit being held in Washington, DC, on September 18th and 19th, 2023.Check out the full program and register online at https://asgct.org/advocacy/policy-summit/agenda
In this podcast episode, our guest is Mark McDonough, CEO of ChromaCode. ChromaCode is an innovator in genomics with a multiplexing platform that is driving integration from laboratories to physicians to patients, connecting them to the right treatment through its proven HDPCR™ multiplexing platform. This adaptable technology expands the accessibility of diagnostic applications to patient communities with a cost effective and scalable dPCR-based solution compatible with existing instrumentation and using standard workflows
In this podcast episode, our guest is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. Medicenna is a clinical stage immunotherapy company that engineers novel, powerful and proprietary interleukins leveraging their Superkine Platform to modulate, fine-tune or amplify the immune system to tackle the most challenging diseases, including a broad range of cancers.
In this podcast episode, Tomasz George, Chief Scientific Officer at Virax Biolabs, shares how the company's ViraxImmune™ technology platform will empower patients to take control of their health and make informed decisions on how to respond to current and future viral threats. The company hopes their ViraxImmune™ platform will shift the way individuals are able to manage aspects of their immune health.
In this podcast episode, Dr. Michael Alonso, VP of Immunology and Pharmacology at Bolt Biotherapeutics, discusses how the company is developing cancer therapies that engage the innate immune system to generate robust anti-tumor responses.
Reneo Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases including mitochondrial diseases with significant unmet medical needs. In this podcast episode, we speak with Gregory Flesher, President and CEO of Reneo to learn more about mavodelpar, the company's lead asset, which is being developed in two rare diseases, primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD).
In this podcast episode, Cyclacel CEO and President, Spiro Rombotis, shares how the company, is exploiting deeper understanding of molecular oncology to develop novel precision medicines based on cell cycle, transcriptional regulation, and mitosis biology.
Chris Leidli reviews scientific and clinical highlights from the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting with guest, Benjamin McLeod, MBIOT.
In this podcast episode, Dr. Philip Kantoff, the CEO, CMO, and Co-Founder of Convergent Therapeutics reviews the company's efforts to develop next-generation radiopharmaceuticals for the treatment of cancer.
FibroBiologics is the leading biotech company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. In this podcast episode, the Founder and CEO, Pete O'Heeron discusses the promise of fibroblast cell therapy to treat diseases such as multiple sclerosis, degenerative disk disease and more.
In this podcast episode, Dr. Erandi De Silva discusses the hybrid approach to gene therapy development at Forge Biologics, Inc., an emerging leader in the contract development and manufacturing (CDMO) market for advanced regenerative medicine products. Dr. De Silva also discusses the unique approach to building a culture and diverse talent pool within the Columbus, Ohio biotech ecosystem.
Forge Biologics is on a mission to enable access to life-changing gene therapies and help bring them from idea into reality. In this podcast episode, we learn about trends in the gene therapy landscape and contract manufacturing from Co-Founder and CEO, Timothy Miller, PhD.
This podcast episode previews the key precision medicine and cellular therapy data being showcased at this year's American Association of Cancer Research annual meeting.
Allen Davidoff, PhD is the Founder and CEO of XORTX Therapeutics, Inc., a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. This podcast episodes looks at novel therapies in development that may extend kidney health.
This podcast episode provides a short recap of the day long workshop hosted by the FDA’s Office of Therapeutic Products (OTP) a new office within CBER. The goal of the workshop was to share knowledge and best practices from experts in the field of advanced manufacturing and analytical technologies (AMAT) for regenerative medicine therapies.Innovative manufacturing technologies and alternative testing methods were discussed along with, challenges and best practices critical for chemistry, manufacturing, and controls (CMC) of cellular and gene therapies and tissue engineered medical products.
As Life Science companies grow, they become less efficient. In this podcast episode, Dr. Donald Davis explains what scaling challenges are and what companies can do to become more efficient using the process improvement tools of lean six sigma.
Anyone who has experimented with ChatGPT can get a sense of the potential of generative AI. AI powers driverless cars, spots signs of disease on medical images, finds an answer when you ask Alexa a question, and lets you unlock your phone with your face to talk to friends on the iPhone. Those are just a few ways AI already touches our lives, but there are many ways AI is being utilized in the pharma industry.Applying AI to big data in pharma will reshape business models, streamline manufacturing, and enhance everything from early drug discovery and clinical trial data to supply chain applications and other market intelligence. It can also enable life sciences companies to be more personalized and authentic in how they engage with health care professionals, patients, and other stakeholders. In this podcast episode, we review the five main applications for AI in biotech, pharma and healthcare.
In this podcast episode, we recap highlights from JPM Healthcare conference with Chris Dokomajilar from DealForma, Inc., and review 2023 outlook for Biopharma Dealmaking, Financing, and Partnerships. To join live webinar on February 8th, 2023, use this link: https://us02web.zoom.us/j/6097872444
In this podcast episode, Chris provides a short preview of biotechnology and pharmaceutical companies to watch in 2023.
This podcast episode covers the highlights from this year’s American Society of Hematology Annual Meeting that took place in New Orleans in early December. There was enormous excitement for novel therapies for blood cancers and for diseases that previously had very high morbidity and mortality and now, because of novel treatment modalities in the field of hematology, like T cell engagers and CAR-T cell therapies, patients outcomes are being improved.
OncoOne is a biotech company developing novel therapeutics for patients with solid tumors and autoimmune diseases. In this podcast episode, Brent Meadows, Chief Business Officer and US General Manager, discusses the role of oxMIF in innate and adaptive immunity and outlines the company's development approach and plan for entering the clinic.
In this podcast episode, our guest, Karoline Eastman, SVP of Customer Experience and Strategy Lead at Pixacore, discusses new digital trends for pharma in 2023 and how to improve HCP and patient customer engagement.
Our guest in this episode is Cove Therapeutics CEO, Niren Shah, who discusses the pitfalls of current viral vector based gene therapies and shares how Cove's next generation non-viral gene delivery platform overcomes many of the challenges of viral vectors.
There are many hurdles to streamlined, cost-effective manufacturing of cell and gene therapy products. To help address this, the Alliance for Regenerative Medicine published A-Cell, a case-based guidebook to help drug developers incorporate Quality by Design (QbD) principles into cell-based therapy CMC programs. A-Cell builds on previous QbD efforts that were applied to the manufacturing of monoclonal antibodies (A-Mab), vaccines (A-Vax), and more recently, gene therapies (A-Gene), bringing best practices in CMC to a case study of a CAR-T therapy manufacturing.
This is the second of a two-part deep dive into the A-Cell document as part of a round table conducted during Meeting on the Mesa. This episode covers key questions around conducting a risk assessment and best practices for product and process characterization for cell therapies.
There are many hurdles to streamlined, cost-effective manufacturing of cell and gene therapy products. To help address this, the Alliance for Regenerative Medicine published A-Cell, a case-based guidebook to help drug developers incorporate Quality by Design (QbD) principles into cell-based therapy CMC programs. A-Cell builds on previous QbD efforts that were applied to the manufacturing of monoclonal antibodies (A-Mab), vaccines (A-Vax), and more recently, gene therapies (A-Gene), bringing best practices in CMC to a case study of a CAR-T therapy manufacturing.
This is the first of a two-part deep dive into the A-Cell document as part of a round table conducted during Meeting on the Mesa. The first podcast episode explores quality by design principles and the importance of the quality target product profile.
The Inflation Reduction Act was signed into law in August 2022 and is one of the most significant pieces of healthcare reform since the Affordable Care Act. In this episode, learn more about how the new policy will impact R&D portfolio decision making and new product development strategies.
The FDA’s Office of Tissues and Advanced Therapies hosted their first virtual town hall to answer industry questions related to gene therapy chemistry, manufacturing, and controls. In this episode, we unpack what happened at the town hall and provide a brief overview of the key insights and guidance from the agency for those developing gene therapies.
Twice a year, the Alliance for Regenerative Medicine (ARM) surveys the cell and gene therapy landscape to advance the field and provide an update to their members, stakeholders, and the public.
In this podcast, Stephen Majors, Senior Director of Public Affairs, reviews key insights from ARM's updated cell and gene therapy sector report for the first half of 2022.
ARM is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.
In this episode, Jan Hannon and Lisa Hefner from BluPrint Oncology dig deeper into scientific and medical communications and how health care provider education has evolved in the post-COVID pandemic era.
In this episode, Paul Callahan, President and Founder of CDT Pharma Strategies discusses market access, trade and distribution best practices for novel therapeutics.
In this episode, Dr. Ramanathan discusses best practices in Pharmaceutical, Biotechnology, and Academic partnerships, alliance management, and innovation.
The biopharma ecosystem is devoting significant resources to develop novel cell and gene therapies to treat cancer. In this episode of "Rx for Biotech", Chris Dokomajilar discusses trends in Biotechnology investment, licensing and partnering landscape and provides an outlook on what to expect for the remainder of 2022.
Our guest in this episode is Dr. Andrew Garst. We discuss the technology behind powerful new genome editing tools that are driving new therapies to treat genomic and inherited human diseases.
During this episode, we explore the key opportunities and challenges with the future commercialization of innovative personalized therapies with our guest, Michael Amoroso, a leader in the cell and gene therapy industry.
In this episode, Dr. Katie Graham reviews FDA regulatory review process for innovative new biotechnology and pharmaceutical products. Dr. Graham shares best practices in helping emerging biotechnology companies accelerate their organizational launch readiness.